4D Molecular Therapeutics annual meeting results: all four proposals approved

4D Molecular Therapeutics, Inc.

Stockholders elected Jacob Chacko, Susannah Gray, and Charles Theuer as Class II directors.
Ratified PricewaterhouseCoopers as independent auditor for FY2025.
Say-on-pay proposal approved (31.8M for, 394k against, 35k abstain, 6.2M broker non-votes).
Advisory vote on future say-on-pay frequency: one year chosen; company will hold annual votes.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.